Clinical Updates

An open-label study of rituximab, a monoclonal antibody for human CD20, was shown to be safe in patients with primary… »   

An experimental drug, clazosentan, reduced the risk of blood vessel spasm in patients with a brain aneurysm, according to research… »   

In patients undergoing hip replacement surgery, using a special wound catheter to infuse local anesthetic directly into the hip joint… »   

Researchers at the University of Southampton, University of Oxford and Retroscreeen Virology Ltd have discovered a series of peptides, found… »   

Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research… »   

A new system for delivering a drug to organ transplant patients, which could avoid the risk of harmful side effects,… »   

Gardasil, the human papillomavirus vaccine that is now recommended for male and female adolescents and young adults, does not trigger… »   

Asthma and gastroesophageal reflux (GER) are both common illnesses in children. GER in children often occurs without the typical symptoms… »   

The brains of people tripping on magic mushrooms have given the best picture yet of how psychedelic drugs work and… »   

Alexza Pharmaceuticals Inc said U.S. health regulators extended the review date for its novel anti-psychotic treatment by three months after… »   

In 2005, news first broke that researchers in Scotland found unexpectedly low rates of cancer among diabetics taking metformin, a… »   

Fears that the U.S. might ban imports of orange juice from Brazil drove orange juice futures to an all-time high… »   

An investigational vaccine protected some women against infection from one of the two types of herpes simplex viruses that cause… »   

Despite concerns that rotavirus vaccines might raise infants’ risk of blocked bowels, a new study finds that hospitalization rates for… »   

Will a drug used to treat childhood acute lymphoblastic leukemia and other pediatric cancers cause heart problems later in life?… »